Advertisement

Zur Pharmakologie positiv inotrop wirkender Pharmaka

  • Hasso Scholz
Conference paper
Part of the Tagung der Deutschen Gesellschaft für Herz- und Kreislaufforschung book series (2849, volume 48)

Zusammenfassung

Unter den positiv inotrop wirkenden Pharmaka sind die Herzglykoside zur langfristigen Therapie der Myokardinsuffizienz nach wie vor die wichtigsten Substanzen. Ihr Wirkungsmechanismus ist im einzelnen nicht bekannt (Lit. s. Akera und Brody 1978, Lüllmann und Peters 1979, Lee et al. 1980, Noble 1980, Greeff 1981). Es besteht Einigkeit, daß sie letztlich in der Zelle zu einer Zunahme der Konzentration an Ca++ ([Ca++]i) fuhren, das mit den kontraktilen Proteinen reagiert. Unklar ist jedoch, wie dies geschieht. Es besteht ebenfalls Einigkeit, daß die Herzglykoside mit der (Na+ + K+)-ATPase reagieren. Eine Hypothese besagt nun, daß eine Hemmung dieses Enzyms eine Steigerung der intrazellulären Na+-Konzentration bewirkt und daß es infolgedessen über eine Änderung des transmembranären Na+/Ca++-Austausches zu einer Steigerung der [Ca++]i kommt. Andere Autoren nehmen an, daß eine derartige Hemmung der (Na+ + K+)-ATPase nur bei toxischen Herzglykosidwirkungen eine Rolle spielt. Sie gehen davon aus, daß die Herzglykoside in „therapeutischer“ Konzentration durch die Reaktion mit der (Na+ + K+)-ATPase zu einer Labilisierung der Ca++-Bindung in der Zellmembran und dadurch während der Erregung zu einer Verbesserung der Ca++-Freisetzung aus sarkolemmalen Ca++-Speichern führen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Akera, T., Brody, T.M.: The role of Na+, K+-ATPase in the inotropic action of digitalis. Pharmacol. Rev. 29: 187–220 (1978).Google Scholar
  2. Alousi, A.A., Farah, A.E., Lesher, G.Y., Opalka, C.J.: Cardiotonic activity of amrinone — Win 40680 (5-amino-3,4’-bipyridin-6(lH)-one). Ore. Res. 45: 666–677 (1979).Google Scholar
  3. Avenhaus, H., Lüderitz, B., Strauer, B.E., Boite, H.-D., Riecker, G.: Kardiale Wirkungen von Glucagon. Dtsch. Med. Wschr. 96: 702–707 (1971).CrossRefGoogle Scholar
  4. Bassingthwaighte, J.B., Reuter, H.: Calcium movements and excitation-contraction coupling in cardiac cells. In: Electrical phenomena in the heart (W.C. de Mello, ed.), pp. 353–395. New York, London: Academic Press 1972.Google Scholar
  5. Benfey, B.G.: Cardiac α adrenoceptors. Can. J. Physiol. Pharmacol. 58: 1145–1157 (1980).PubMedCrossRefGoogle Scholar
  6. Benotti, J.R., Grossman, W., Braunwald, E., Carabello, B.A.: Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 62: 28–34 (1980).PubMedGoogle Scholar
  7. Benotti, J.R., Grossman, W., Braunwald, E., Davolos, D.D., Alousi, A.A.: Hemodynamic assessment of amrinone. A new inotropic agent. N. Engl. J. Med. 299: 1373–1377 (1978).Google Scholar
  8. Blinks, J.R., Olson, C.B., Jewell, B.R., Braveny, P.: Influence of caffeine and other methylxanthines on mechanical properties of isolated mammalian heart muscle. Evidence for a dual mechanism of action. Circ. Res. 30: 367–392 (1972).Google Scholar
  9. Bolton, T.B.: Mechanisms of action of transmitters and other substances on smooth muscle. Physiol. Rev. 59:606–718 (1979).PubMedGoogle Scholar
  10. Bourdillon, P.D.V., Dawson, J.R., Foale, R.A., Timmis, A.D., Poole-Wilson, P.A., Sutton, G.C: Salbutamol in treatment of heart failure. Br. Heart J. 43: 206–210 (1980).PubMedCrossRefGoogle Scholar
  11. Bruckner, R., Hackbarth, I., Meinertz, T., Schmelzle, B., Scholz, H.: The positive inotropic effect of phenylephrine in the presence of propranolol. Increase in time to peak force and in relaxation time without increase in c-AMP. Naunyn-Schmiedeberg’s Arch. Pharmacol. 303: 205–211 (1978).Google Scholar
  12. Chapman, R.A.: Excitation-contraction coupling in cardiac muscle. Prog. Biophys. Mol. Biol. 35: 1–52 (1980).CrossRefGoogle Scholar
  13. Colucci, W.S., Alexander, R.W., Mudge, G.H., Rude, R.E., Holman, B.L., Wynne, J., Grossman, W., Braunwald, E.: Acute and chronic effects of pirbuterol on left ventricular ejection fraction and clinical status in severe congestive heart failure. Am. Heart J. 102: 564–568 (1981).PubMedCrossRefGoogle Scholar
  14. Cyran, J., Bolte, H.-D.: Kombinierte Infusion von Nitroprussid-Natrium und Dobutamin zur Behandlung der hochgradigen Linksherzinsuffizienz bei koronarer Herzkrankheit. Klin. Wschr. 57: 883–891 (1979).PubMedCrossRefGoogle Scholar
  15. Dahmen, M., Greeff, K.: Analysis of the positive-inotropic activity of the benzimidazole derivate AR-L 115 BS in isolated guinea pig atria. Arzneim.-Forsch. (Drug Res.) 31: 161–165 (1981).Google Scholar
  16. Dawson, J.R., Canepa-Anson, R., Kuan, P., Whitaker, N.H.G., Carnic, J., Warnes, C, Reuben, S.R., Poole Wilson, P.A., Sutton, G.C.: Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. Br. Med. J. 282: 1423–1426 (1981).CrossRefGoogle Scholar
  17. Diederen, W., Kadatz, R.: Comparative cardiovascular effects of three benzimidazole derivatives, AR-L 57 BS, AR-L 100 BS, and AR-L 115 BS. Arzneim.Forsch. (Drug Res.) 31: 141–146 (1981).Google Scholar
  18. Diederen, W., Weisenberger, H.: Studies on the mechanism of the positive-inotropic action of AR-L 115 BS, a new cardiotonic drug. Arzneim.-Forsch. (Drug Res.) 31: 177–182 (1981).Google Scholar
  19. Dönges, C, Heitmann, M., Jungbluth, H., Meinertz, T., Schmelzle, B., Scholz, H.: Effectiveness of theophylline to increase cyclic AMP levels and force of contraction in electrically paced guinea-pig auricles. Comparison withisoprenaline, calcium andouabain. Naunyn-Schmiedeberg’s Arch. Pharmacol. 301: 87–97 (1977).Google Scholar
  20. Drummond, G.I., Severson, D.L.: Cyclic nucleotides and cardiac function. Circ. Res. 44: 145–153 (1979).PubMedGoogle Scholar
  21. Fabiato, A., Fabiato, F.: Calcium release from the sarcoplasmic reticulum. Circ. Res. 40: 119–129 (1977).PubMedGoogle Scholar
  22. Farah, A.E., Alousi, A.A.: New cardiotonic agents: a search for digitalis substitute. Life Sci. 22: 1139–1148 (1978).PubMedCrossRefGoogle Scholar
  23. Goldberg, L.I.: Dopamine — Clinical uses of an endogenous catecholamine. N. Engl. J. Med. 291: 707–710 (1974).PubMedCrossRefGoogle Scholar
  24. Goldberg, L.I., Hsieh, Y.-Y., Resnekov, L.: Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Prog. Cardiovasc. Dis. 19: 327–340 (1977).PubMedCrossRefGoogle Scholar
  25. Greeff, K. (ed.): Cardiac Glycosides. Handbook of Experimental Pharmacology 56/1, pp. 1–682. Berlin, Heidelberg, New York: Springer 1981.Google Scholar
  26. Hackbarth, L, Schmitz, W., Scholz, H., Erdmann, E., Krawietz, W., Philipp, G.: Stimulatory effect of vanadate on cyclic AMP levels in cat papillary muscle. Biochem. Pharmacol. 29: 1429–1432 (1980).PubMedCrossRefGoogle Scholar
  27. Hedberg, A., Minneman, K.P., Molinoff, P.B.: Differential distribution of beta-1 and beta-2 adrenergic receptors in cat and guinea-pig heart. J. Pharmacol. Exp. Ther. 213: 503–508 (1980).Google Scholar
  28. Herzig, J.W., Feüe, K., Rüegg, J.C.: Activating effects of AR-L 115 BS on the Ca2+ sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian cardiac muscle. Arzneim.-Forsch. (Drug Res.) 31: 188–191 (1981).Google Scholar
  29. Honerjäger, P., Schäfer-Körting, M., Reiter, M.: Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn-Schmiedeberg’s Arch. Pharmacol. 318: 112–120 (1981).Google Scholar
  30. Irmer, M., Wollschläger, H., Just, H.: Behandlung der schweren Herzinsuffizienz mit dem Beta-Stimulator Fenoterol. Klin. Wochenschr. 59: 639–645 (1981).PubMedCrossRefGoogle Scholar
  31. Katz, A.M.: Physiology of the heart. New York: Raven Press 1977.Google Scholar
  32. Katz, A.M.: A new inotropic drug: its promise and a caution. N. Engl. J. Med. 299: 1409–1410 (1978).PubMedCrossRefGoogle Scholar
  33. Katz, A.M.: Role of the contractile proteins and sarcoplasmic reticulum in the response of the heart to catecholamines: An historical review. Adv. Cycl. Nucleot. Res. 11: 303–343 (1979).Google Scholar
  34. Katz, A.M.: Relaxing effects of catecholamines in the heart. Trends Pharmacol. Sci. 1: 434–436 (1980).CrossRefGoogle Scholar
  35. Kerr, C.R.: Hemodynamic effects of oral salbutamol in patients with severe left ventricular failure. Circulation 60 (Suppl. II): 11–41 (1979).Google Scholar
  36. Kirlin, P.C., Pitt, B.: Hemodynamic effects of intravenous prenalterol in severe heart failure. Am. J. Cardiol. 47: 670–675 (1981).PubMedCrossRefGoogle Scholar
  37. Kones, R.J., Phillips, J.H.: Glucagon: present status in cardiovascular disease. Clin. Pharmacol. Ther. 12: 427–444 (1971).PubMedGoogle Scholar
  38. Korth, M.: Effects of several phosphodiesterase — inhibitors on guinea-pig myocardium. NaunynSchmiedeberg’s Arch. Pharmacol. 302: 77–86 (1978).CrossRefGoogle Scholar
  39. Krause, E.-G., Wollenberger, A.: Cyclic nucleotides and heart. In: Cyclic 3’,5’-Nucleotides: Mechanisms of Action (H. Cramer, J. Schultz, eds.), pp. 229–250. London: Wiley 1977.Google Scholar
  40. Kruse, E., Scholz, H.: Effect of theophylline on myocardial adenylate cyclase activity. Experientia 34: 504–505 (1978).PubMedCrossRefGoogle Scholar
  41. Kukovetz, W.R., Pöch, G., Holzmann, S.: Cyclic nucleotides and relaxation of vascular smooth muscle. In: Vasodilatation (P.M. Vanhoutte, I. Leusen, eds.), pp. 339–353. New York: Raven Press 1981.Google Scholar
  42. Langer, G.A.: The structure and function of the myocardial cell surface. Am. J. Physiol. 235: H461–468 (1978).Google Scholar
  43. Langer, G.A.: The role of calcium in the control of myocardial contractility: An update. J. Mol. Cell. Cardiol. 12: 231–239 (1980).PubMedCrossRefGoogle Scholar
  44. Lee, C.O., Kang, D.H., Sokol, J.H., Lee, K.W.: Relation between intracellular Na ion activity and tension of sheep cardiac Purkinje fibers exposed to dihydroouabain. Biophys. J. 29: 315–330 (1980).PubMedCrossRefGoogle Scholar
  45. LeJemtel, T.H., Keung, E., Sonnenblick, E.H., Ribner, H.S., Matsumuto, M., Davis, R., Schwartz, W., Alousi, A.A., Davolos, D.: Amrinone: A new nonglycosidic, non-adrénergie cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation 59: 1098–1104 (1979).Google Scholar
  46. Limbourg, P., Just, H., Kersting, F., Lang, K.F.: Kardiovaskuläre Effekte von Dobutamin. Klin. Wschr. 56: 551–557 (1978).PubMedCrossRefGoogle Scholar
  47. Liillmann, H., Peters, T.: Action of cardiac glycosides on the excitation-contraction coupling in heart muscle. A new concept. Progr. Pharmacol. 2/2: 1–58 (1979).Google Scholar
  48. Lüttgau, H.C., Glitsch, H.G.: Membrane physiology of nerve and muscle fibres. Forschr. Zool. 24: 1–132 (1976).Google Scholar
  49. Mason, D.T., Braunwald, E., Cohn, J.N. (eds.): New modalities in the management of heart failure. Am. Heart J. 102: 485–642 (1981).Google Scholar
  50. Mason, D.T., Awan, N.A., Amsterdam, E.A., Lee, G., Joye, J.A., Foerster, J.M., Laslett, L.J., Low, R.I., DeMaria, A.N.: New therapeutic approaches to the failing heart: Recent advances in vasodilators, cardiotonics, and mechanical circulatory assistance. Adv. Heart. Dis. 3: 403–446 (1980).Google Scholar
  51. Millard, R.W., Dubé, G., Grupp, G., Grupp, I., Alousi, A., Schwartz, A.: Direct vasodilator and positive inotropic actions of amrinone. J. Mol. Cell. Cardiol. 12:647–652 (1980).PubMedCrossRefGoogle Scholar
  52. Miura, Y., Inui, J., Imamura, H.: Alpha-adrenoceptormediated restoration of calcium-dependent potential in the partially depolarized rabbit papillary muscle. Naunyn-Schmiedeberg’s Arch. Pharmacol. 301:201–205 (1978).CrossRefGoogle Scholar
  53. Mugelli, A., Ledda, F., Mantelli, L., Torrini, M., Maccioni, T.: Studies on the positive inotropic effect of dopamine in the guinea-pig heart. NaunynSchmiedeberg’s Arch. Pharmacol. 301: 49–55 (1977).CrossRefGoogle Scholar
  54. Nimmo, H.G., Cohen, P.: Hormonal control of protein phosphorylation. Adv. Cycl. Nucleot. Res. 8: 145–266 (1977).Google Scholar
  55. Noble, D.: Mechanism of action of therapeutic levels of cardiac glycosides.Cardiovasc. Res. 14:495–514 (1980).Google Scholar
  56. Ochs, H.R., Bodem, G.: Alternativen zur Digitalistherapie? Dtsch. Med. Wschr. 106: 583–586 (1981).CrossRefGoogle Scholar
  57. Oltmanns, D., Wester, H.-A., Stein, R.: Echokardiographisch ermittelte Dosis-Wirkungs-Beziehung von Prenalterol. Z. Kardiol. 70: 394–398 (1981).PubMedGoogle Scholar
  58. Opie, L.H.: Drugs and the heart. V. Digitalis and sympathomimetic stimulants. Lancet 1: 912–918 (1980).Google Scholar
  59. Osnes, J.-B., Skomedal, T., 0ye, L: On the role of cyclic nucleotides in the heart muscle contraction and relaxation. Progr. Pharmacol. 4: 47–62 (1980).Google Scholar
  60. Owen, D.A.A.: Histamine receptors in the cardiovascular system. Gen. Pharmae. 8: 141–156 (1977).CrossRefGoogle Scholar
  61. Parmley, W.W.:The role ofglucagonin cardiac therapy. N. Engl. J. Med. 285: 801–802 (1971).Google Scholar
  62. Piepenbrock, S., Hempelmann, G., Reichelt, W., Stegmann, Th.: Hämodynamische und selektive vaskuläre Effekte von Dobutamin während und nach herzchirurgischen Eingriffen. Anaesthesist 28: 307–315 (1979).PubMedGoogle Scholar
  63. Piepenbrock, S., Reichelt, W., Zenz, M., Scitz, W., Sikalieh, E.: Prenalterol (CGP 7760 B), ein neuer kardioselektiver ßj-Rezeptoren-Agonist. Anaesthesist 30: 118–123 (1981).PubMedGoogle Scholar
  64. Reinhardt, D.: Herzwirkungen von Histamin. Differenzierung unterschiedlicher Rezeptoren, Physiologie und Biochemie des Wirkmechanismus. Anaesthesist 28: 67–77 (1979).Google Scholar
  65. Reinhardt, D., Schmidt, U., Brodde, O.-E., Schümann, HJ.: H,-und H2-receptor mediated responses to histamine on contractility and cyclic AMP of atrial and papillary muscles from guinea-pig hearts. Agents/Actions 7: 1–12 (1977).Google Scholar
  66. Reiter, M.: Drugs and heart muscle. Annu. Rev. Pharmacol. 12: 111–124 (1972).PubMedCrossRefGoogle Scholar
  67. Reuter, HL: Divalent cations as charge carriers in excitable membranes. Progr. Biophys. Mol. Biol. 26: 1–43 (1973).CrossRefGoogle Scholar
  68. Reuter, H.: Localization of beta adrenergic receptors, and effects of noradrenaline and cyclic nucleotides on action potentials, ionic currents and tension in mammalian cardiac muscle. J.Physiol. (Lond.) 242: 429–451 (1974a).Google Scholar
  69. Reuter, H.: Exchange of calcium ions in the mammalian myocardium. Mechanisms and physiological significance. Circ. Res. 34: 599–605 (1974b).Google Scholar
  70. Reuter, H., Scholz, H.: The regulation of the calcium conductance of cardiac muscle by adrenaline. J. Physiol. (Lond.) 264: 49–62 (1977).Google Scholar
  71. Rodgers, R.L., MacLeod, K.M., McNeill, J.H.: Responses of rat and guinea pig hearts to glucagon. Lack of evidence for a dissociation between changes in myocardial cyclic 3’,5’-adenosine monophosphate and contractility. Circ. Res. 49: 216–225 (1981).Google Scholar
  72. Rönn, O., Johnsson, G., Lundborg, P.: Interaction in healthy volunteers between prenalterol, a selective β1-adrenoceptor agonist, and metoprolol or propranolol. J. Cardiovasc. Pharmacol. 3: 477–484 (1981).PubMedCrossRefGoogle Scholar
  73. Rude, R.E., Turi, Z., Brown, E.J., Lorell, B.H., Colucci, W.S., Mudge, G.H., Taylor, C.R., Grossman, W.: Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. Circulation 64: 139–145 (1981).PubMedCrossRefGoogle Scholar
  74. Sanehez-Chapula, J.: Differential effects of histamine on left and right guinea-pig atria. Eur. J. Pharmacol. 74: 253–256 (1981).CrossRefGoogle Scholar
  75. Schmitz, W., Hackbarth, I., Scholz, H., Wetzel, E.: Effects of vanadate on the c-AMP system of the heart. Basic Res. Cardiol. 75: 438–443 (1980).PubMedCrossRefGoogle Scholar
  76. Scholz, H.: Effects of beta-and alpha-adrenoceptor activators and adrenergic transmitter releasing agents on the mechanical activity of the heart. Handbook of Experimental Pharmacology Vol. 54/1, Adrenergic activators and inhibitors, Part I (L. Szekeres, ed.), pp. 651–733. Berlin, Heidelberg, New York: Springer 1980.Google Scholar
  77. Scholz, H.: On the mechanism of action of theophylline on the heart and other organs. In: Methods in Clinical Pharmacology, Vol. 4, Theophylline and other Methylxanthines (N. Rietbrock, B.G. Woodcock, A.H. Staib, eds.), pp. 99–105. Braunschweig/Wiesbaden: Vieweg 1982.Google Scholar
  78. Scholz, H., Bruckner, R.: Effects of alpha-adrenoceptor stimulating agents on cardiac mechanical and electrophysiological properties. Abstracts 8th International Congress of Pharmacology, p. 512, Tokyo 1981.Google Scholar
  79. Schümann, HJ.: Are there a-adrenoceptors in the mammalian heart? Trends Pharmacol. Sci. 1: 195–197 (1980).CrossRefGoogle Scholar
  80. Schümann, HJ., Motomura, S., Endoh, M., Brodde, O.-E.: Comparison of the mechanisms underlying the positive inotropic actions of dopamine, adrenaline and isoprenaline on the isolated rabbit papillary muscle. Naunyn-Schmiedeburg’s Arch. Pharmacol. 297: 257–267 (1977).CrossRefGoogle Scholar
  81. Sharma, B., Goodwin, J.F.: Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on systolic and diastolic function of the left ventricle. Circulation 58: 449–460 (1978).Google Scholar
  82. Sharma, B., Hoback, J., Francis, G.S., Hodges, M., Asinger, R.W., Cohn, J.N., Taylor, C.R.: Pirbuterol: A new oral sympathomimetic amine for the treatment of congestive heart failure. Am. Heart J. 102: 533–541 (1981).PubMedCrossRefGoogle Scholar
  83. Slutsky, R., Hooper, W., Gerber, K., Curtis, G., Karliner, J., Ashburn, W.: The effect of terbutaline on left ventricular function and size. Am. J. Cardiol. 45:412(1980).Google Scholar
  84. Sobel, B.E., Mayer, S.E.; Cyclic adenosine monophosphate and cardiac contractility. Circ. Res. 32: 407–414 (1973).PubMedGoogle Scholar
  85. Sonnenblick, E.H., Frishman, W.H., Le Jemtel, T.H.: Dobutamine: A new synthetic cardioactive sympathetic amine. N. Engl. J. Med. 300: 17–22 (1979).PubMedCrossRefGoogle Scholar
  86. Sulakhe, P.V., St. Louis, P.J.: Passive and active calcium fluxes across plasma membranes. Prog. Biophys. Mol. Biol. 35: 135–195 (1980).PubMedCrossRefGoogle Scholar
  87. Sutherland, E.W., Robison, G.A., Butcher, R.W.: Some aspects of the biological role of adenosine 3’,5’ monophosphate (cyclic AMP). Circulation 37: 279–306 (1968).Google Scholar
  88. Symposium über AR-L 115 BS (Vardax®). Arzneim.Forsch. (Drug Res.) 31: 129–278 (1981).Google Scholar
  89. Taylor, C.R., Baird, J.R.C., Blackburn, K.J., Cambridge, D., Constantine, J.W., Ghaly, M.S., Hayden, M.L., Mcllhenny, H.M., Moore, P.F., Olukotun, A.-Y., Pullman, L.G., Salsburg, D.S., Saxton, C.A.P.D., Shevde, S.: Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. Am. Heart J. 102: 515–532 (1981).PubMedCrossRefGoogle Scholar
  90. Tsien, R.W.: Cyclic AMP and contractile activity in heart. Adv. Cycl. Nucleot. Res. 8: 363–420 (1977).Google Scholar
  91. Verma, S.C., McNeill, J.H.: Cardiac histamine receptors and cyclic AMP. Life Sci. 19: 1797–1802 (1976).PubMedCrossRefGoogle Scholar
  92. Verma, S.C., McNeill, J.H.: Cardiac histamine receptors: differences between left and right atria and right ventricle. J. Pharmacol. Exp. Ther. 200: 352–362 (1977).PubMedGoogle Scholar
  93. Waagstein, F., Reiz, S., Ariniego, R., Hjalmarson, A.: Clinical results with prenalterol in patients with heart failure. Am. Heart J. 102: 548–554 (1981).PubMedCrossRefGoogle Scholar
  94. Williams, J.F.: New developments and therapeutic applications of cardiac stimulating agents. Am. J. Cardiol. 32: 491–496 (1973).PubMedCrossRefGoogle Scholar
  95. Winegrad, S.: Electromechanical coupling in heart muscle. In: Handbook of Physiology, Section 2, The Cardiovascular System, Vol. 1, The Heart (R.M. Berne, ed.), pp. 393–428. Bethesda: American Physiological Society 1979.Google Scholar
  96. Wollenberger, A., Will, H.: Protein kinase — catalyzed membrane phosphorylation and its possible relationship to the role of calcium in the adrenergic regulation of cardiac contraction. Life Sci. 22: 1159–1178 (1978).PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1982

Authors and Affiliations

  • Hasso Scholz
    • 1
  1. 1.Abteilung Allgemeine PharmakologieUniversitäts-Krankenhaus EppendorfHamburg 20Deutschland

Personalised recommendations